Intra-Cellular Therapies Statistics
Total Valuation
CTO has a market cap or net worth of $541.53 million. The enterprise value is $1.14 billion.
Important Dates
The last earnings date was Tuesday, July 29, 2025, after market close.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Jun 12, 2025 |
Share Statistics
CTO has 32.94 million shares outstanding. The number of shares has increased by 33.30% in one year.
| Current Share Class | 32.94M |
| Shares Outstanding | 32.94M |
| Shares Change (YoY) | +33.30% |
| Shares Change (QoQ) | +3.58% |
| Owned by Insiders (%) | 8.72% |
| Owned by Institutions (%) | 67.85% |
| Float | 29.99M |
Valuation Ratios
| Price/FFO Ratio | 13.33 |
| Price/AFFO Ratio | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.51 |
| Forward PS | 3.51 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 7.04 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.07 |
| EV / EBITDA | 13.36 |
| EV / EBIT | 78.09 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.68, with a Debt / Equity ratio of 1.06.
| Current Ratio | 0.68 |
| Quick Ratio | 0.44 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | 7.15 |
| Debt / FCF | n/a |
| Interest Coverage | 0.60 |
Financial Efficiency
Return on equity (ROE) is -5.66% and return on invested capital (ROIC) is 0.84%.
| Return on Equity (ROE) | -5.66% |
| Return on Assets (ROA) | 0.81% |
| Return on Invested Capital (ROIC) | 0.84% |
| Return on Capital Employed (ROCE) | 1.26% |
| Revenue Per Employee | $3.81M |
| Profits Per Employee | -$1.02M |
| Employee Count | 37 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 121.60 |
Taxes
| Income Tax | -60,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.09% in the last 52 weeks. The beta is 0.54, so CTO's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -18.09% |
| 50-Day Moving Average | 17.76 |
| 200-Day Moving Average | 18.87 |
| Relative Strength Index (RSI) | 33.46 |
| Average Volume (20 Days) | 320,503 |
Short Selling Information
The latest short interest is 1.52 million, so 4.61% of the outstanding shares have been sold short.
| Short Interest | 1.52M |
| Short Previous Month | 1.00M |
| Short % of Shares Out | 4.61% |
| Short % of Float | 5.06% |
| Short Ratio (days to cover) | 3.68 |
Income Statement
In the last 12 months, CTO had revenue of $141.00 million and -$37.66 million in losses. Loss per share was -$1.26.
| Revenue | 141.00M |
| Gross Profit | 104.52M |
| Operating Income | 14.56M |
| Pretax Income | 16.81M |
| Net Income | -37.66M |
| EBITDA | 85.10M |
| EBIT | 14.56M |
| Loss Per Share | -$1.26 |
Full Income StatementBalance Sheet
The company has $13.82 million in cash and $609.58 million in debt, giving a net cash position of -$595.76 million or -$18.09 per share.
| Cash & Cash Equivalents | 13.82M |
| Total Debt | 609.58M |
| Net Cash | -595.76M |
| Net Cash Per Share | -$18.09 |
| Equity (Book Value) | 574.06M |
| Book Value Per Share | 17.43 |
| Working Capital | -25.34M |
Full Balance SheetCash Flow
| Operating Cash Flow | 76.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 74.13%, with operating and profit margins of 10.33% and -21.38%.
| Gross Margin | 74.13% |
| Operating Margin | 10.33% |
| Pretax Margin | -21.42% |
| Profit Margin | -21.38% |
| EBITDA Margin | 60.36% |
| EBIT Margin | 10.33% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $1.52, which amounts to a dividend yield of 9.21%.
| Dividend Per Share | $1.52 |
| Dividend Yield | 9.21% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.30% |
| Shareholder Yield | -24.09% |
| Earnings Yield | -6.95% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for CTO is $22.00, which is 33.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.00 |
| Price Target Difference | 33.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2022. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 2022 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
